● ChromaLIVE™

Go beyond the limits of cell painting to profile drugs in high-content imaging

ChromaLIVE™: differentiate cell phenotypes like never before

More Live-Cell Dyes

● NucleoLIVE™ Non-Toxic Dye

A non-toxic nuclear dye providing new cell proliferation data

Go beyond tedious transfections or endpoint cell viability assays based on ATP detection, and open the door to new cell viability data in high-throughput screens

● MortaLIVE™ Non-Toxic Dye

Live-dead assays made easier and more insightful

Mix-and-read assay to easily study cell viability and cytotoxicity in real time over multiple days

Frequently Asked Questions

Interested in our live cell dyes?

Join the 150+ biotech and pharma companies using Saguaro's non-toxic dyes for new insights

Thanks for contacting us. We'll get back to you as soon as possible.

Get in touch with us

Testimonials

“ChromaLIVE™ has completely transformed our cell screening workflows. Its non-toxic, wash-free protocol gives similar data to cell painting, but with additional insights[...] This new tool has allowed us to identify novel hits and mechanistic insights from prior campaigns.”
Dr. Simon MathienHTS Platform Lead Institute for Research in Immunology and Cancer at IRIC

Dr. Simon Mathien
HTS Platform Lead Institute for Research in Immunology and Cancer at IRIC

“The unbiased, data-rich insights provided by ChromaLIVE™ have been a game-changer in stratifying CLL patient cohorts[...] allowing us to identify new patient cohorts with predictable drug responses, something not possible with conventional clinical criteria or traditional in vitro assays.”
Dr. David Andrews
Dr. David Andrews

Director of and senior scientist in Biological Sciences at Sunnybrook Research Institute

“After testing the Saguaro dyes, we immediately saw the value in changing how we screen drugs in our 3D organoid systems[...] NucleoLIVE™, MortaLIVE™ and ChromaLIVE™ showed superior penetration, enabling clear visualization of cells in the organoid core, critical for monitoring cell death and effects of hypoxia.”
Dr. Magnar Bjørås
Dr. Magnar Bjørås

Professor of Medicine at NTNU